$MRSH

Doyle John Q sold $2.7M of MRSH

Doyle John Q (President and CEO) sold 16,656 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $161.71 ($2.69M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Doyle John Q
Published Jun 3, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MRSH
Neutral
medium confidence
Mentioned
$MRSH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The disclosure updates the record of management’s equity transactions; it does not by itself change company fundamentals.

02

Market read

Traders may monitor for sentiment/flow effects, but the 10b5-1 framing suggests limited directional conviction.

03

What to watch

Sale size is meaningful, but without context on total holdings, prior sales cadence, and whether the plan is regularly used, the signal may be overstated.

Relevance 6/10Novelty 6/10Timing: Filed today; sale occurred on 2026-06-02

Background

The article is an SEC insider transaction disclosure (Form 4) for Marsh & McLennan Companies, Inc. (MRSH).

Company-level read

Ticker impact

$MRSHNeutralMedium confidence
Context

SEC Form 4 shows MRSH CEO sold 16,656 shares in an open-market transaction worth about $2.69M under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment/flow-driven rather than fundamental.

Evidence & confidence

The filing provides a concrete sale size and price, but the transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

Minimal—single-company insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated or large-value sales can still coincide with management’s private view of near-term risk or liquidity needs.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Doyle John Q

    President and CEO who sold shares.

  • Rule 10b5-1 plan

    Indicates the sale was pre-arranged, typically lowering interpretive weight.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRSHMedAI 8/10

Why Marsh (MRSH) Stock Is Trading Up Today

Marsh (MRSH) shares rose 4.7% after reporting Q3 2026 results with 8% revenue growth and 10% increase in adjusted EPS. GAAP earnings were $1.69, adjusted earnings $2.03. The company repurchased $500M in stock and raised its savings target to $600M. Shares closed at $186.43, up 4.5%.

$MRSHHighAI 8/10

Marsh McLennan earnings analysis: questions answered and next catalysts

Marsh McLennan (MRSH) reported Q3 FY2026 earnings on Oct 15, 2026, beating estimates with EPS of $2.03 and revenue of $6.86B. The stock rose 5.49% to $188.19. Analysts had lowered price targets before the report, contributing to the rally. Key questions remain about organic growth durability and valuation. Next catalysts include Q4 earnings, 2027 guidance, and analyst revisions.

$MRSHHighAI 8/10

Marsh McLennan (MRSH) Q3 2026 Earnings Call Transcript

Marsh McLennan (MRSH) reported Q3 2026 earnings with revenue up 8%, adjusted operating income up 6%, and adjusted EPS up 10%. The company highlighted growth in consulting and risk services, increased Thrive savings target to $600M, and progress in AI integration. They also repurchased $500M in stock. Market conditions showed mixed rate changes across regions and lines of business.